Standard Lurbinectedin Dosage
Lurbinectedin (Zepzelca) is FDA-approved at a fixed dose of 3.2 mg/m² administered intravenously over 60 minutes on day 1 of a 21-day cycle for adults with metastatic small cell lung cancer (SCLC) that has progressed on or after platinum-based chemotherapy.[1][2]
Dosages for Other Cancers
No FDA-approved dosages exist for cancers beyond SCLC. Clinical trials and compassionate use have tested lurbinectedin in other solid tumors, but these use the same 3.2 mg/m² dose or close variations (e.g., 3.5 mg flat dose or 2.0 mg/m² in combinations), without cancer-specific adjustments.[3][4]
Dose Adjustments and Reductions
Dosage does not vary by cancer type but requires reductions for toxicity:
- First reduction: 2.4 mg/m²
- Second reduction: 2.0 mg/m²
- Permanent discontinuation below 2.0 mg/m²
Adjust for liver impairment (e.g., max 2.0 mg/m² if bilirubin >1.5x ULN) or drug interactions like strong CYP3A inhibitors (reduce to 2.0 mg/m²).[1][2]
Ongoing Trials in Other Cancers
Trials explore lurbinectedin in non-SCLC cancers like pleural mesothelioma, ovarian cancer, and sarcomas, typically at 3.2 mg/m² monotherapy or lower in combos (e.g., 1.0-2.0 mg/m² with doxorubicin). No divergent dosing protocols have emerged.[3]
[1]: Zepzelca (lurbinectedin) prescribing information, Jazz Pharmaceuticals, https://www.zepzelca.com/
[2]: FDA approval summary for Zepzelca, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213069s000lbl.pdf
[3]: ClinicalTrials.gov searches for lurbinectedin (NCT02454972, NCT02830337, etc.)
[4]: DrugPatentWatch.com, Lurbinectedin patent and trial data, https://www.drugpatentwatch.com/p/tradename/ZEPZELCA